- Home
- HSCS vs PCSA Comparison
HSCS vs PCSA Comparison
Compare HSCS & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- PCSA
- Stock Information
- Founded
- HSCS 2007
- PCSA 2011
- Country
- HSCS United States
- PCSA United States
- Employees
- HSCS N/A
- PCSA N/A
- Industry
- HSCS Medical Specialities
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- PCSA Health Care
- Exchange
- HSCS Nasdaq
- PCSA Nasdaq
- Market Cap
- HSCS 3.7M
- PCSA 3.3M
- IPO Year
- HSCS 2022
- PCSA N/A
- Fundamental
- Price
- HSCS $3.87
- PCSA $0.22
- Analyst Decision
- HSCS Strong Buy
- PCSA Strong Buy
- Analyst Count
- HSCS 2
- PCSA 1
- Target Price
- HSCS $13.00
- PCSA $6.00
- AVG Volume (30 Days)
- HSCS 68.9K
- PCSA 46.5M
- Earning Date
- HSCS 07-28-2025
- PCSA 08-12-2025
- Dividend Yield
- HSCS N/A
- PCSA N/A
- EPS Growth
- HSCS N/A
- PCSA N/A
- EPS
- HSCS N/A
- PCSA N/A
- Revenue
- HSCS N/A
- PCSA N/A
- Revenue This Year
- HSCS N/A
- PCSA N/A
- Revenue Next Year
- HSCS N/A
- PCSA N/A
- P/E Ratio
- HSCS N/A
- PCSA N/A
- Revenue Growth
- HSCS 261.17
- PCSA N/A
- 52 Week Low
- HSCS $2.36
- PCSA $0.15
- 52 Week High
- HSCS $5.77
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- HSCS 52.06
- PCSA 44.28
- Support Level
- HSCS $3.66
- PCSA $0.20
- Resistance Level
- HSCS $4.03
- PCSA $0.33
- Average True Range (ATR)
- HSCS 0.30
- PCSA 0.09
- MACD
- HSCS 0.01
- PCSA -0.01
- Stochastic Oscillator
- HSCS 41.11
- PCSA 6.53
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).